WO2018075018A1 - Kits, compositions et procédés de traitement et de recouvrement de la peau - Google Patents

Kits, compositions et procédés de traitement et de recouvrement de la peau Download PDF

Info

Publication number
WO2018075018A1
WO2018075018A1 PCT/US2016/057550 US2016057550W WO2018075018A1 WO 2018075018 A1 WO2018075018 A1 WO 2018075018A1 US 2016057550 W US2016057550 W US 2016057550W WO 2018075018 A1 WO2018075018 A1 WO 2018075018A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
skin
composition
components
adhesion promoters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/057550
Other languages
English (en)
Inventor
Shien-Lin Saber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio-Silicote Inc
Original Assignee
Bio-Silicote Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Silicote Inc filed Critical Bio-Silicote Inc
Priority to PCT/US2016/057550 priority Critical patent/WO2018075018A1/fr
Publication of WO2018075018A1 publication Critical patent/WO2018075018A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Definitions

  • the field of the invention is skin treatment and coverage.
  • exemplary products include hydrocolloid blister pads with adhesive films, pre-formed silicone gel sheets including an adhesive backing, gel callus cushions having a central hole and an adhesive backing, and 2 nd Skin® knit pads, a breathable non-woven fabric including a medical grade adhesive, which protects blisters against rubbing and frictions.
  • Some polymerizable film-forming compositions are also known in the art, although they are generally applicable and used to hide skin imperfections where there is no injury.
  • U.S. Patent No, 8,691,202 to Yu et al. teaches cosmetic formulations that comprise a cross-linking component and a reactive reinforcing component, wherein the cross-linking component facilitates in situ cross-linking of the reactive reinforcing component such that a film is formed on the skin.
  • This and all other extrinsic materials discussed herein are incorporated by reference in their entirety. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
  • Yu is apparently directed only to cosmetic compositions that reduce the appearance of skin or body imperfections such as under eye bags, sagging, uneven skin tone, redness, and wrinkles. Because Yu's contemplated uses are cosmetic in nature, only a very thin layer is applied, and there is apparently no significant structural integrity for use of Yu's composition in the context of an injury. Furthermore, many of Yu's compositions began to crack or peel within a few hours of application, and specific cleansers were used for complete removal.
  • the inventive subject matter comprises kits, compositions and methods for protecting a user's skin, and for treating a skin injury or imperfection using a polymerizable composition.
  • the films formed from contemplated polymerizable compositions can advantageously have sufficient elasticity such that the adhesion strength of the film is greater than the counterforce applied to the injury and skin by the film. Additionally, the film can have mechanical properties such that it does not easily tear, and can provide a protective layer to the skin for at least one day or at least two days that can be pulled off as a single piece (even after being worn for a period of at least one day, at least two days, or even three days or more).
  • Contemplated methods can comprise applying a first silicone-containing elastomer component to the skin injury, applying a second silicone-containing elastomer component to the skin injury, and mixing the first and second components to form, within ten minutes, a film having a thickness and tensile strength effective to compress the user's skin and decrease formation of fibroblasts.
  • the elastomer components could be applied to the skin and mixed directly on the skin, or the elastomer components could be mixed together prior to being applied to the skin injury, and the mixed components can be applied in a single step.
  • the first and second components can be applied in substantially equal volumes (e.g., within 5 vol%, more preferably within 1 vol%), for example through a dual- chambered syringe having a mixing tip.
  • skin injury includes any injury on or near the surface of the skin where tendons, muscles, ligaments, nerves, blood vessels or bone are not exposed to the environment. Exemplary skin injuries can include minor burns, superficial wounds, scars and keloids.
  • polymerizable compositions presented herein could also be suitable for other types of injuries, for example, deep wounds that cut deeper than 1 ⁇ 2 inch, wherein tendons, muscles, ligaments, nerves, blood vessels or bone may be exposed to the environment through an opening in the user's skin.
  • the two silicone-containing elastomer components will preferably separately include a catalyst and a cross-linker such that premature curing of the polymerizable composition is avoided.
  • the first component can comprise between .05-.2 wt% of a silicone platinum catalyst, between 70-90 wt% of a polydimethyl siloxane polymer and between 15-29.8 wt% fumed silica
  • the second component can comprise between 70-90 wt% of a polydimethyl siloxane polymer, between 15-29 wt% fumed silica, and between 1-10 wt% of a siloxane polymer cross-linker.
  • the ingredients in a polymerizable composition can be separated into three, four, or even more components to be combined prior to use.
  • the polymerizable composition (the combination of the two or more components) can comprise between 70-90 wt% (e.g., 75-85 wt%) of a siloxane polymer, between 15-29.8wt% (e.g., 15-25 wt%) of a fumed silica, between 0.1-0.3 wt% (or between 0.025-0. lwt%) of the catalyst, and between .5-5wt% (e.g., 1-5 wt%) of a cross-linker.
  • a film (optionally water-resistant) having a thickness and tensile strength effective to compress the user's skin can form within ten minutes, more preferably within five minutes or within two minutes, and adhere to the user's skin for a period of at least six hours.
  • the polymerizable composition can include one or more adhesion promoters, optionally in synergistic amounts, to increase the adhesion time or the adhesion strength of the film to the user's skin.
  • a base composition e.g., a mineral powder, cleanser, primer, a liquid spray, a gel
  • the base composition, the polymerizable composition (or both) can optionally include one or more of an anesthetic, an antiseptic, an adhesion promoter, a fumed silica, a botanical (e.g., chamomile, marigold, arnica, plant extract), a drug, a vitamin (e.g., ascorbic acid, retinol, niacinamide), an antipruritic, a catalyst, a haemostatic agent, and a vasoconstrictor.
  • the additional ingredients will in some preferred aspects not be present in an amount that significantly prolongs cure time of the polymerizable composition or decreases adhesion strength of the seal.
  • Contemplated polymerizable compositions upon forming a seal in situ, will preferably be elastic or semi-elastic.
  • some contemplated compositions will have an elongation at break of at least 200%, more preferably at least 300%, and more preferably at least 400% (e.g., between 200-1000%, between 400 and 800%, between 450-600%), to allow for movement and stretching of the body without compromising the seal.
  • the polymerizable compositions are used in different applications, or in areas of skin that does not require significant elasticity, it is contemplated that the polymerizable composition can have a lower elongation at break, or even be inelastic or substantially inelastic.
  • some preferred polymerizable compositions will have a hardness sufficient to prevent unwanted flowing of the seal.
  • some contemplated seals will have a hardness of at least 10 on the Shore 00 durometer scale, and more preferably at least 10 on the Shore A scale.
  • the polymerizable composition can be formulated such that the film formed can decrease formation of fibroblasts, press down blisters, or decrease a biochemical cascade that promotes scar formation.
  • Some contemplated films can be water resistant and remain adhered to the user's skin for a period of at least 24 hours, at least 48 hours or at least 72 hours, and even through events where the skin is exposed to water (e.g., swimming, bathing, showering).
  • compositions and methods for treating or covering skin by forming a thin film or seal using a composition that polymerizes in situ are contemplated, including vinyl- based cure systems, silicone-based cure systems, peroxide-cure systems, heat cure systems, room temperature vulcanizing moisture cure systems, temperature activated systems, photoinitiated cure systems, and addition-cure systems. Additionally, all suitable polymerization reactions are contemplated, including hydrosilylation polymerization, condensation polymerization, and addition (chain-growth) polymerization (e.g., photopolymerization), and radical polymerization.
  • the polymerizable composition will result in a cured film or seal having sufficient elasticity to allow the user to move around comfortably without the edges lifting, or adding to the pain or discomfort to the user.
  • the polymerizable composition is typically odorless, non-toxic, hypoallergenic, compatible with other treatments, bacteriostatic, non-explosive, non-temperature sensitive, and removable as a single piece, or in sections, after curing.
  • the polymerizable composition can comprise a one part system, for example, where the polymerizable composition is temperature or light activated.
  • the polymerizable composition can comprise a multi-component (multi-part) system, for example, where a catalyst and a cross-linking component must be separated to prevent premature and undesired curing.
  • a first elastomer component including a catalyst, and a second elastomer component including a cross-linker are applied to the skin, for example over a skin injury to be treated, or a portion to be camouflaged.
  • the first and second components are combined prior to, during or after application to form, within ten minutes (e.g., within five minutes), a polymerized water- resistant film having an elongation at break of at least 150%.
  • the composition can additionally or alternatively include any of the components described herein, including for example, two or more adhesion promoters present in synergistic amounts with respect to adhesion of the film to the skin.
  • kits for skin treatment or coverage which include a pre-formed polymerized composition, and a multi-component polymerizable composition.
  • the multi-component polymerizable composition can comprise first and second silicone-containing elastomer components that separately include one or more silicone catalysts and one or more silicone cross-linkers.
  • the first and second silicone-containing elastomer components can be formulated to, when applied between skin and the pre-formed polymerized composition, form a water-resistant film that adheres to each of the skin and the pre-formed polymerized composition within ten minutes, more preferably within five minutes.
  • methods of adhering pre-formed composition to skin include the steps of applying first and second silicone-containing elastomer components to at least one of the preformed composition and the user's skin.
  • the first and second components can be combined and positioned between the pre-formed composition and the skin to form a polymerized film, within five minutes, that adheres to each of the skin and the pre-formed composition for a period of at least 12 hours, more preferably at least 18 hours, and even more preferably at least 24 hours.
  • Some preferred polymerizable compositions comprise a multi-part elastomer system that cures at room or body temperature and includes (a) a first formulation or component including a polymer and catalyst (e.g., siloxane polymer and platinum catalyst), and (b) a second formulation or component comprising a polymer and a cross-linker.
  • a first formulation or component including a polymer and catalyst e.g., siloxane polymer and platinum catalyst
  • a second formulation or component comprising a polymer and a cross-linker.
  • One or both of the formulations could include one or more of a filler, a thixotropic agent, a drug, a vitamin, a botanical, an adhesion promoter, a cure inhibitor to control the cure kinetics, or any multiples or combinations thereof.
  • first and second formulations are separately packaged or contained in a dual chambered system, crosslinking can be prevented until the two components are mixed together (e.g., layered or applied as a mixture).
  • the polymer is a silicone polymer (siloxane polymer) with a polymer backbone of alternating silicone and oxygen atoms (i.e., siloxane bonds), and hydrocarbon (saturated, unsaturated, aromatic) organic side groups such as methyl, phenyl or vinyl, or a hydrogen attached to the silicon atoms.
  • silicone polymer silicone polymer
  • oxygen atoms i.e., siloxane bonds
  • hydrocarbon (saturated, unsaturated, aromatic) organic side groups such as methyl, phenyl or vinyl, or a hydrogen attached to the silicon atoms.
  • the siloxane polymer(s) can comprise between 20-100wt%, more preferably at least 50wt% (e.g., between 60-90wt%), and even more preferably at least 70wt% (e.g., between 75-85wt%, between 78-82wt%) of the polymerizable composition (i.e., of the combined two part formulation where the catalyst and cross-linker are combined).
  • PDMS polystyrene-maleic anhydride
  • it can be a linear polymer made up of repeating Si-O-Si linkages and a reactive vinyl group on both ends of the polymer chain. There may be organic side groups such as dimethyl bonded to every silicone molecule the backbone of the polymer. Siloxane polymers can also be substituted with diphenyl, methylphenyl, trifluoropropyl, or any combination thereof.
  • Some exemplary siloxanes include oligosiloxanes, polydimethylsiloxane (PDMS), vinyl-endblocked polydiphenyl siloxane, vinyl-endblocked polymethylphenylsiloxane, vinyl-endblocked trifluoropropyl siloxane, vinyl-endblocked polydiethyl siloxane, trimethyl- endblocked methylvinyl polydimethylsiloxane, trimethyl-endblocked methylvinyl
  • Contemplated siloxanes can be optically clear, non-toxic and nonflammable.
  • All suitable chain lengths of the siloxane polymer are contemplated, including between 10-2,500 repeating units long, between 200-1,000 repeating units long (or a molecular weight of between 20,000-32,000 Daltons), or between 300-400 repeating units long (e.g., 340-360), which equates to a molecular weight of ⁇ 26,000 Daltons.
  • a polymer can include a main chain formed primarily of organosiloxane units.
  • silicone compounds contemplated, some may display both curing and adhesive properties, for example depending on the proportion of silicone or whether they are used with a particular additive. It may therefore be possible to adjust the properties of said compositions according to the proposed use.
  • a siloxane cross- linker such as a methyl-hydrogen cross-linker can be included.
  • the cross-linker(s) can comprise between . l-50wt%, between . l-10wt%, between 2-10wt%, and more preferably between l-5wt% (e.g., 2wt%) of the polymerizable composition.
  • An exemplary siloxane cross-linker used in some contemplated compositions is a small chain polymer that is trimethyl endblocked, making the ends of the chain non-functional.
  • All suitable chain lengths of the cross-linker are contemplated, including for example, between 1-100 repeating units, more preferably between 1-50 units, and more preferably between 5-15 units and having a molecular weight of between 400-1,200 Daltons (e.g., 10 units wherein the molecular weight is approximately 800 Daltons).
  • Along the backbone of the cross-linker can be reactive methyl-hydrogen side groups which can comprise between 1-99 mole %, more preferably between 20-80 mole %, and more preferably between 40- 60 mole% (e.g., 50 mole %) of the cross-linker.
  • the remaining mole % can comprise dimethyl side groups. Where each of the methyl-hydrogen side groups and the dimethyl side groups make up approximately 50 mole%, approximately half of the repeating units of the cross-linker will be dimethyl, and approximately half will be methyl hydrogen.
  • cross-linkers include hydride-endblocked polydimethylsiloxane, hydride-endblocked methylhydrogen polysiloxane, trimethyl-endblocked methylhydrogen methylvinyl polysiloxane, trimethyl-endblocked 100 mole% methylhydrogen polysiloxane, hydride-endblocked polydiphenylsiloxane, and hydride-endblocked phenylhydrogen
  • cross-linkers described above are siloxane cross -linkers, it should be appreciated that a person skilled in the art would be able to select a suitable cross- linker based on the polymer included in the polymerizable compositions.
  • the catalysts of contemplated polymerizable formulations can comprise a peroxide, platinum, tin, a combination thereof, or other suitable catalyst.
  • An exemplary platinum catalyst for hydro silylation reactions can comprise a complex of platinum with a vinyl siloxane acting as a ligand. An example of this is the Karstedt's catalyst.
  • contemplated catalysts include, rhodium complex in vinly silicone fluid, organotin catalyst such as dibutyltin dilaurate, stannous octoate, dibutlytin diacetate, peroxide catalysts such as benzoyl peroxide, 2,4 dichlorobenzoyl peroxide, dicumyl peroxide, 2,5-Dimethyl-2,5-di(tert-butylperoxy)hexane.
  • organotin catalyst such as dibutyltin dilaurate, stannous octoate, dibutlytin diacetate
  • peroxide catalysts such as benzoyl peroxide, 2,4 dichlorobenzoyl peroxide, dicumyl peroxide, 2,5-Dimethyl-2,5-di(tert-butylperoxy)hexane.
  • the catalyst(s) can be present in the formulation in any suitable amount, for example, between 0.001- 10wt% (of the combined two part formulation where the catalyst and cross-linker are combined), more preferably between 0.01 and lwt%, more preferably between .06-.3wt%, and more preferably between 0.07 and 0.13wt% (e.g., 0.1wt%) of the polymerizable
  • composition and can include between l-250ppm, between 5-70ppm, more preferably between 15-60ppm (e.g., 30ppm) of pure platinum.
  • the platinum catalyst (or at least a portion of the platinum catalyst) will preferably be separated from the cross-linker until placed within, or on, the injury. Alternatively or
  • the platinum catalyst can be combined with the cross-linker no more than 5 minutes, no more than 3 minutes, and referably no more than 1 minute or 0.5 minute prior to being placed within, or on, the injury.
  • the component or formulation comprising the platinum catalyst can be placed within the injury before or after the formulation or component comprising the cross-linker is placed within, or on, the injury.
  • a base composition e.g., spray
  • a base composition comprising the same or different catalyst could be applied prior to any of the first formulation (including the platinum catalyst) and the second formulation (including the cross -linker).
  • an exemplary filler includes amorphous fumed silica having a surface area of between 100-300 m /gram (e.g., between 150-
  • contemplated fillers include fumed silica with low surface area (e.g., 100 m /gram), fumed silica with high surface area (e.g., 400 m /gram), precipitated silica, diatomaceous earth, titanium dioxide, zinc oxide, barium sulfate, colloidal silica, and boron nitride.
  • the filler can comprise between 0-90wt%, more preferably between 5-35wt% and even more preferably between 10-23wt% (e.g., 16wt%) of the combined two part formulation where the catalyst and cross-linker are combined.
  • the surface of the silica can be treated with trimethyl silyl groups so that it is more soluble with the polymer.
  • a suitable thixotropic additive e.g., a compound that reduces the flowability of a material rendering it non- slump
  • the thixotrope can comprise between .1- 5wt%, between .5-2.5wt%, and more preferably between l-2wt% (e.g., 1.5wt%) of the combined two part formulation where the catalyst and cross-linker are combined.
  • An exemplary thixotrope included in some contemplated formulations is a hydroxyl endblocked polydimethyl siloxane with a chain length of between 10-20 repeating units (e.g., 15 repeating units with a molecular weight of 1100 Daltons).
  • the hydroxyl groups on the polymer ends can react with the surface hydroxyl groups of the fumed silica causing the silica to become less flowable.
  • Suitable adhesion promoters can also be included in the polymerizable composition to increase the bond strength of the adhesive (polymerizable composition or seal) to the substrate (skin) or tissue as curing occurs.
  • Tetrapropoxysilane is an exemplary adhesion promoter commonly used in silicone primers. Without wishing to be bound by any particular theory, the applicant contemplates that the reactive silane may form hydrogen or even covalent bonds with the skin.
  • the adhesion promoter(s), when included in the polymerizable composition can comprise between 0.01-20wt%, between 0.01-10wt%, between 0.1 and 5wt%, between 0.5- 5wt%, between l-3wt%, between 0.1-2wt%, and more preferably between 0.4 and 1.2wt% (e.g., 0.8wt%) of the polymerizable composition.
  • Additional adhesion promoters suitable for contemplated polymerizable formulations include those shown in Table 1. Equal parts of the first and second components including the different adhesion promoters were mixed and a thin layer was applied to a forearm and allowed to vulcanize at room temperature. The samples were evaluated by recording the time that the edges began to lift from the skin. Once the edges lifted, the samples were peeled off and evaluated qualitatively for how difficult it was to peel complete off the skin. Each adhesion promoter was evaluated, and the results are described in Table 1 below. All percentages used herein are weight percentages (wt%) unless otherwise indicated. Formulation of table 2 with 1%
  • compositions including 0.25% N- (triethoxysilylpropyl)-O-polyethylene oxide urethane began lifting after 6.5 hours, and compositions including 1.5% Tetrapropoxysilane began lifting after 5 hours
  • compositions including both 1.5% Tetrapropoxysilane and 0.25% N-(triethoxysilylpropyl)-0-polyethylene oxide urethane did not begin to lift for 18 hours, and had an "excellent" adhesion to skin.
  • N-(triethoxysilylpropyl)-0-polyethylene oxide urethane was used in combination with other adhesion promoters, synergistic effects were not found, and only moderate changes in lift time were found (e.g., + 1 hour).
  • the combination of at least two adhesion promoters can increase at least one of an adhesion time and an adhesion strength of the film or seal to the skin by at least 5%, more preferably at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or even at least 50% or more when compared to one of the two or more adhesion promoters alone as present in the same concentration as the combination of the at least two adhesion promoters.
  • the film formed by a polymerizable composition having at least two adhesion promoters in synergistic amounts can have an edge that entirely adheres to the skin for at least 6 hours, at least 12 hours, at least 15 hours, or even at least 18 hours under normal conditions.
  • an edge that entirely adheres to skin means that all edges of the film remains adhered to the skin without any edge portion lifting.
  • normal conditions should be interpreted broadly to include stretching and flexing of the user's skin (e.g., in connection with walking, exercising, working) without any direct application of force to the film. It is also contemplated that the film formed can entirely adhere to the skin for at least 1 hour, at least 3 hours, at least 6 hours, at least 12 hours, at least 15 hours, or even at least 18 hours even when direct force is applied to the film (e.g., when showering, bathing, rubbing, swimming).
  • inert pigments can be suspended in the polymerizable formulations without leaching into the wound or body.
  • Suitable uses for inert pigments can include visibility, aesthetics (e.g., with designs), identification, or camouflaging (e.g., flesh tones, bright tones, or any other suitable tones).
  • Some contemplated powdered pigments can advantageously be broken down to a size of less than 20 microns, more preferably less than 15 microns to allow for even distribution or dispersion throughout the polymerizable formulation.
  • concentrated liquid or gum color pigments can be added to one or more components of the polymerizable formulation.
  • Pigments or colorants can be included in the polymerizable composition at between .001- 10wt%, between .01-6wt%, or in any other suitable amount.
  • the pigments will not substantially negatively affect the physical properties of the polymerizable composition or the film formed, including for example, the hardness, the tensile strength, the elongation at break, and tear resistance.
  • the pigments or colorants will not change the hardness, the tensile strength, the elongation at break or tear resistance by more than 10%, more preferably not more than 5%.
  • Radio opaque or other particles e.g., barium sulfate, zirconium dioxide
  • Radio opaque or other particles could be suspended or otherwise incorporated into the polymerizable formulations such that the cured seal can be detected by X-ray, computed tomography scans, ultrasound imaging or MRI scans.
  • at least 2wt%, at least 5wt%, more preferably at least 8wt% e.g., between l-50wt%, between 8-50wt%, between 5-30wt%, between 8-10wt%, between 10- 20wt%) is included in the combined two part polymerizable formulation for detection by X-ray.
  • the radio opaque particles could be added to the polymerizable formulation in any commercially suitable matter, and could even be pre-mixed with one or more of its components.
  • the radio opaque particles could be mixed in with the first formulation component, second formulation component, silicone polymer, platinum catalyst, cross-linker, adhesion promoter, cure inhibitor, filler, thixotropic agent, or any combination thereof.
  • first and second formulations can react with each other at various temperatures, including for example at temperatures between -20 and 80 degrees Celsius, more typically between 0 and 60 degrees Celsius, and even more typically between 10 and 50 degrees Celsius.
  • the formulations will be capable of reacting together to form a seal at room temperature (20+5° C) and atmospheric pressure, or
  • a complete seal can be formed within 20 minutes, within 10 minutes, more preferably within five minutes, within three minutes, within two minutes, or even within one minute.
  • the seal can have any suitable thickness to treat or manage the injury, for example a thickness of between 0.1 mm and 50 mm, between 1 mm and 40 mm, between 1 mm and 20 mm, between 1 mm and 10 mm, or between 1 mm and 5 mm.
  • the seal can have a hardness sufficient to prevent unwanted flowing of the seal.
  • the seal can have a hardness of at least 10 on the Shore 00 durometer scale, at least 10 on the Shore A scale, a hardness of between 0 on the Shore 00 durometer scale and 40 on the Shore A durometer scale, a hardness of between 10 on the Shore 00 durometer scale and 30 on the Shore A durometer scale, a hardness of between 15-25 on the Shore A durometer scale, or a hardness of between 18-22 on the Shore A durometer scale.
  • the work time of the polymerizable composition can be approximately half of the cure time (e.g., about sixty seconds where the cure time is about two minutes).
  • the seal can have an elasticity that allows for movement and stretching of the body without compromising the seal or causing discomfort or pain.
  • some contemplated compositions will have an elongation at break of at least 200%, more preferably at least 300%, and more preferably at least 400% (e.g., between 200-1000%, between 400 and 800%, between 450-600%).
  • the term "% elongation at break” refers to the extension of a length of a cured seal from an unstretched and normal configuration before tearing, at room temperature, wherein the cured seal has a thickness of between 3 -5mm in the unstretched, normal configuration.
  • the cured seal when normally having a thickness of between 3-5mm, can be stretched to at least 180% of its length before tearing (e.g., from 10mm to at least 18mm before tearing).
  • the seal can have a tensile strength that allows significant force to be applied while maintaining its integrity (e.g., between 100-2000psi, between 200-800psi, between 400-650psi).
  • the seal or film can have a leather adhesive force of at least 50 N/mm, at least 60 N/mm, at least 70 N/mm, at least 80 N/mm, at least 90 N/mm, at least 100 N/mm, or at least 125 N/mm when a layer between 3-5mm of a contemplated polymerizable composition is applied to and sandwiched between two strips of soft flexible leather at room temperature, set for 30 minutes, and peeled at a 180 degree angle at a rate of lOmm/s.
  • Table 3 shows an exemplary two part polymerizable formulation having a dual adhesion promoter system.
  • the two adhesion promoters work synergistically to increase adhesion to skin when compared to formulations having only one of the adhesion promoters.
  • Applicant contemplates that one adhesion promoter makes the second more available at the surface of the formulation.
  • adhesion promoters in this example are provided in Part 2 of the formulation, it should be appreciated that one adhesion promoter could be provided in each of Parts 1 and 2, that both adhesion promoters could be provided in Part 1, or that one adhesion promoter could be provided in the polymerizable formulations while a second adhesion promoter is provided in a base composition.
  • the formulation of Table 1 has a working time of between 20-40 seconds (typically about 30 seconds), and a setting time of between 4-6 minutes (typically about 5 minutes) when Part 1 and Part 2 are mixed together and placed on skin.
  • Table 3 [0018] It is also contemplated that the components shown in Table 1 could be included in Parti and Part 2 of the formulation in different concentration ranges as set forth below in Table 4 with comparable work times (e.g., between 10-120 seconds), setting times (e.g., between 1-10 minutes), adhesion properties (as described in Table 1), hardness of between 5-80 on the ShoreA hardness scale, tensile strength between 200-1500 psi, and elongation at break (of between 200- 1000%).
  • work times e.g., between 10-120 seconds
  • setting times e.g., between 1-10 minutes
  • adhesion properties as described in Table 1
  • hardness of between 5-80 on the ShoreA hardness scale tensile strength between 200-1500 psi
  • elongation at break of between 200- 1000%.
  • Table 4 shows an exemplary formulation including barium sulfate, which is contemplated to have comparable work times (e.g., between 10-120 seconds), setting times (e.g., between 1-10 minutes), adhesion properties, hardness, tensile strength, and elongation at break as the formulation of Table 1.
  • Table 5 shows an exemplary formulation including one or more pigments, which is contemplated to have comparable work times (e.g., between 10-90 seconds), setting times (e.g., between 1-10 minutes), adhesion properties, and elongation at break as the formulation of Table 1.
  • Tables 7-10 show exemplary formulations only including one adhesion promoter, which is contemplated to have comparable work times (e.g., between 10-90 seconds), setting times (e.g., between 1-10 minutes), hardness, tensile strength, and elongation at break as the formulation of Table 1, but a lower adhesion strength to skin likely due to a lack of synergistic effect with a second adhesion promoter.
  • Table 11 shows an exemplary formulation including a thixo tropic agent added to make the formulation non-slump at a concentration of between 0.25-3wt%.
  • the formulation of Table 10 is contemplated to have comparable work times (e.g., between 10-90 seconds), setting times (e.g., between 1-10 minutes), adhesion properties, hardness, tensile strength, and elongation at break as the formulation of Table 1.
  • Table 12 shows another exemplary formulation including less platinum catalyst than the formulation of Table 1, which is contemplated to require a longer cure time.
  • Table 12 [0024] Table 13 shows another exemplary formulation including less cross-linker than the formulation of Table 1, which is contemplated to require a longer cure time.
  • Tables 15 and 16 show other exemplary compositions that can be used for some of the uses described herein, although the compositions would not have the adhesion strength or time of some of the above-referenced formulations.
  • Silicone dioxide non-crystalline 3-13 Silicone dioxide, non-crystalline 3-13
  • ingredients described herein can be obtained from different commercial suppliers.
  • components of some contemplated polymerizable compositions or base component can be obtained from commercial suppliers, for example, Silbond Corporation, Chemat, H.W. Sands Corp., Fluorochem USA, Gelest, Inc., Dupont Performance chemicals, Nusil Technology, Power Chemical Corporation, Rhodia Silicones, Reliance Silicones, or Zentek.
  • base compositions are applied to the injury, for example prior to applying the polymerizable composition that forms a seal
  • such base compositions could comprise at least one of an anesthetic, an antiseptic, an adhesion promoter, an antipruritic, a catalyst, a haemostatic agent, a vitamin, a botanical, a drug, and a vasoconstrictor.
  • the base composition could advantageously provide one or more of a pain relieving, therapeutic, antimicrobial, or blood coagulative effect.
  • the base composition could act as or include a primer that promotes adhesion of the
  • the base composition will not negatively impact the polymerizable composition's ability to adhere to the skin or tissue, or to cure in situ in a short amount of time.
  • Contemplated local anesthetics include, among others, xylocaine, lidocaine, lignocaine, bupivacaine, benzocaine, tetracaine (amethocaine), ropivacaine, prilocaine, procaine, cinchocaine, mepivacaine and etidocaine.
  • Each local anesthetic (or the combination of anesthetics) can be present in the base composition in any suitable amount.
  • the local anesthetic can be present in a spray, ointment, jelly or other composition in any suitable concentration, including for example, a concentration of between 1- 500 mg/ml, between 1-250 mg/ml, between 5-100 mg/ml, or between 5-50 mg/ml. If the local anesthetic (or other base ingredient) is included in the polymerizable composition, for example instead of or in addition to the base, it is contemplated that the same, lower or higher
  • concentration of the local anesthetic could be included.
  • Contemplated antiseptics include benzalkonium chloride, tea tree oil, alcohol, hydrogen peroxide, iodine, and boric acid.
  • Each antiseptic (or the combination of antiseptics) can be present in the base composition in any suitable amount.
  • the antiseptic can be present in the base (e.g., a spray, ointment, jelly, other composition) in any suitable concentration, incluiding for example, a concentration of between .1-100 mg/ml, between .1-50 mg/ml, between .1-10 mg/ml, between .1-5 mg/ml, or between .8-1.8 mg/ml.
  • the antiseptic can be present in the base composition at a concentration of between 0.01-1.0 w/w%, between 0.01-.5 w/w%, or between 0.08-.18 w/w%.
  • Contemplated adhesion promoters can include a silane coupling agent containing one or more functional groups that bond with the polymerizable composition or components thereof.
  • Some contemplated adhesion promoters include a tetramethoxysilane, a tetraethoxysilane, a tetraisopropoxy silane, a tetrapropoxy silane, a tetrabutoxysilane, and a tetraacetoxysilane, a 3- aminopropropyltrimethoxysilane, tris(2-methoxyethoxy)(vinyl)silane, vinyltriethoxysilane, tetrakis(2-methoxyethyl)ester, and trimethoxy-7-octenylsilane.
  • An adhesion promoter where included in the base composition can be the same as or different from the adhesion promoter(s) included in a polymerizable composition. Additionally or alternative, the base composition could comprise one adhesion promoter of a synergistic pair, while the polymerizable composition could comprise another adhesion promoter of the synergistic pair.
  • the adhesion promoter(s) can be present in the base composition in any suitable amount.
  • the adhesion promoter can be present in a spray, ointment, jelly, powder or other type of base composition in any suitable concentration, including for example, a concentration of between .1-100 mg/ml, between .1-75 mg/ml, between .1-50 mg/ml, between .1-10 mg/ml, or between .5-10 mg/ml.
  • Vasoconstrictors can be included in contemplated base compositions, and can have several beneficial effects, for example, when added to a local anesthetic.
  • the vasoconstrictor can decrease the peak plasma concentration of the local anesthetic agent, increase the duration and quality of the anesthesia, reduce the minimum concentration of anesthetic needed for nerve blocking, and decrease the amount of blood lost.
  • Contemplated vasoconstrictors include epinephrine, norepinephrine, vasopressin, oxymetazoline,
  • phenylephrine anhydrous aluminum sulfate, and pseudoephedrine.
  • the vasoconstrictor(s) can be present in the base composition in any suitable amount.
  • the vasoconstrictor can be present in a spray, ointment, jelly or other type of base composition in any suitable concentration, including for example, a concentration of between .1-100 mg/ml, between .1-75 mg/ml, between .1-50 mg/ml, between .1-10 mg/ml, or between .5-10 mg/ml.
  • antipuritic component(s) can be present in the base composition in any suitable amount.
  • the antipuritic can be present in a spray, ointment, jelly or other composition in any suitable concentration, including for example, a concentration of between 1-500 mg/ml (.1-50%), between 1-100 mg/ml (.1-10%), or between 1-50 mg/ml (.1-5%).
  • haemostatic agent could also be included in contemplated base compositions to slow down or stop a bleed when applied directly on the source.
  • haemostatic agents include antifibrinolytics, blood coagulation factors, fibrinogen, vitamin K, microfibrillar collagen hemostat (MCH), chitosan hemostats, and thromboplastin.
  • the base composition can also include a silicone or other catalyst that promotes curing of the polymerizable composition, which can be present in any suitable concentration (e.g., between .001-50 mg/ml).
  • a catalyst included in the base composition could be the same as or different from one or more catalysts included in the polymerizable formulation.
  • botanicals can be included in the base composition, including for example, plant extracts (e.g., chamomile extract, gotu kola extract, boswellia serrata extract, green tea extract) or other active components of plants (e.g., curcumin).
  • plant extracts e.g., chamomile extract, gotu kola extract, boswellia serrata extract, green tea extract
  • other active components of plants e.g., curcumin.
  • the plant extract(s) can be included at between 0.01-20 wt%, more preferably less than 10 wt%, and even more preferably less than 5 wt%.
  • Exemplary primer base compositions can comprise one or more reactive silanes, a catalyst, and a solvent carrier (among other things).
  • the reactive silanes can include a reactive group that is compatible with the polymerizable composition, and another reactive group that is compatible with the substrate (e.g., skin, tissue) to thereby promote adhesion of the polymerizable composition to the substrate.
  • One exemplary silicone primer comprises between 88-93 wt% isopropyl alcohol (e.g., 88 wt%), between 1-5 wt% tetrapropoxy silane (e.g., 3%), between 1-5 wt% titanium IV butoxide (e.g., 3%), and between 0.01-2 wt% or .5-2wt% of a platinum catalyst (e.g., 1 wt%).
  • a platinum catalyst e.g. 1 wt%
  • Pre-Formed Compositions [0045]
  • the polymerizable compositions discussed above can be used in combination with preformed compositions of any suitable shape (e.g., strips, tubes), for example, to at least partially secure the pre-formed composition in place on a user's skin. All suitable pre-formed
  • the pre-formed composition can include an existing object such as a tube, a strip of material, or a jewelry item or other accessory.
  • the pre-formed object can be a piece of cured material that is made from the polymerizable composition, for example a pre-formed strip of material that is rolled up and can be flattened / unrolled for use. Viewed from a different perspective, custom silicone sheets or strips could be formed using the polymerizable compositions of the inventive subject matter.
  • One exemplary use of pre-formed materials and a polymerizable composition is to secure an oxygen nasal cannula or other tubing in place on a user's skin such that is can be safely and gently removed, even of a baby or infant's skin.
  • Some known methods exist typically involving taping the cannula to the user's face.
  • certain tapes can be painful to remove and even damage the user's face, while others have a weak adhesive and can easily be pulled off by the user.
  • the preformed strip e.g., a cured piece of the polymerizable composition
  • small amounts of the polymerizable composition can be placed on opposite ends of the pre-formed material, and pressed upon the user's skin. The tubing would then be secured in place under the pre-formed material.
  • the cannula or other tubing could be the pre-formed material, and the polymerizable composition can be used to adhere the cannula or other tubing directly to the skin. It is contemplated that the cured polymerizable composition can adhere to various pre-formed composition for a period of at least 6 hours, a period of at least 12 hours, a period of at least 18 hours, a period of at least 1 day, a period of at least 2 days, a period of at least 3 days, or even up to one week during normal activity.
  • pre-formed material is as breast tape, breast lifts or pasties.
  • a square or triangular strip of material could be adhered to a lower portion of the breast (or under the breast) using the polymerizable composition.
  • the non-adhered end of the material could be lifted over the breast and secured to the user's skin (e.g., at the user's shoulder, collar bone, back, upper chest) once the breast is at a desired position (e.g., desired lift and cleavage).
  • a desired position e.g., desired lift and cleavage
  • an existing breast lift could be adhered to the skin with the breast placed in the desired position.
  • the pre-formed material could comprise a gel or silicone nipple cover, which can be adhered to the user's breast around the user's nipple to avoid or reduce pain from removal.
  • the polymerizable compositions of the inventive subject matter could also be used to camoflauge or treat wrinkles, under-eye bags, or any other portion of the skin where greater skin elasticity is desired.
  • the user's skin could be stretched to reduce the appearance of the wrinkles or the under-eye bag, and the first and second elastomer components can be mixed and applied to the stretched skin (in any suitable order).
  • the polymerizable composition can help hold the skin in the stretched configuration to improve the appearance of the user's skin even after the cured film is removed, for example by reducing the appearance of wrinkles.
  • the polymerizable composition can be applied over a treatment composition (e.g., vitamin A acid, alpha hydroxyl acids, antioxidants, moisturizers, vitamin C, retinol), or the polymerizable composition can include the treatment composition(s).
  • a treatment composition e.g., vitamin A acid, alpha hydroxyl acids, antioxidants, moisturizers, vitamin C, retinol
  • the treatment compositions can be more effectively delivered to the user's skin as unwanted removal (e.g., on clothing, hands) can be avoided.
  • the polymerizable compositions can also be used as a post-tattoo treatment in place of an ointment and plastic wrap or other known treatments and protectors.
  • the formed film can have edges that are adhered to the user's skin around the tattoo, and can act to seal entry points into the skin and body to prevent infections. Additionally or alternatively, the entire film can adhere to the user's skin.
  • the preformed film can be placed over an ointment or other treatment composition, and adhered to the user's skin along the edge portions such that the ointment stays in place and the pre-formed film can adhere to the skin for a longer period of time (e.g., between 1-14 days, between 1-7 days, between 1-5 days, between 1-3 days, between 2-5 days, between 2-4 days, between 2-3 days, between 3-4 days).
  • a longer period of time e.g., between 1-14 days, between 1-7 days, between 1-5 days, between 1-3 days, between 2-5 days, between 2-4 days, between 2-3 days, between 3-4 days.
  • the polymerizable composition can include pigments (e.g., pigments having skin tones), which can be used to effectively cover up a tattoo for long periods of time (e.g., at least 24 hours, at least 48 hours, between 24 and 72 hours, between at least 24-48 hours) when compared to most make-up cover up formulations.
  • the pigmented composition can be mixed and applied to the user's skin (in any other) over a tattoo to be covered up, and the film formed within five minutes can remain adhered to the skin for a period of at least 24 hours, at least 48 hours, at least 72 hours or even more.
  • the elasticity and adhesion properties of the film allows for long term wear.
  • polymerizable compositions can be applied to have decorative features or designs that can be applied as a temporary tattoo.
  • compositions described herein can also be used for topical
  • Applicant contemplates use of the compositions on areas of skin affected by rosacea or other skin disorders, with or without suitable treatment compositions (e.g., metronidazole).
  • suitable treatment compositions e.g., metronidazole
  • compositions can also be applied as a polymerizable band-aid or skin protector that prevents or protects from picking or scratching, for example when the user suffers from allergies or excoriation disorders.
  • Skin bolstering uses are also contemplated, for example, to hold a flap or portion of skin in place.
  • the compositions can be used to push back and secure an eyelid away from the globe of the eye, or to hold a skin graft in place.
  • the cured compositions could also be as ear plugs, for example, to protect the ear drum from water (e.g., while swimming), from loud sounds (e.g., at concerts), and from external objects that could cause injury to the ear.
  • the compositions can be applied to seal an entry point of a tube or other foreign object.
  • a chest tube or other device is entering the body (e.g., drainage tubes for breast augmentations, abdominoplasty)
  • the polymerizable composition can be used to secure the tube in place, to seal the entry point, and to decrease the likelihood of an infection.
  • contemplated applications include, among other things, custom-made vaginal pessaries, cervical caps or diaphragms, shielding of specific areas of skin during a laser treatment or chemical peel, or to protect skin during hair dye applications, and prevention of premature suture removal, or of suture filaments grabbing onto clothing, gauze or other materials.
  • Coupled to is intended to include both direct coupling (in which two elements that are coupled to each other contact each other) and indirect coupling (in which at least one additional element is located between the two elements). Therefore, the terms “coupled to” and “coupled with” are used synonymously.
  • inventive subject matter provides example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des kits, des compositions et des procédés de traitement ou de recouvrement de la peau à l'aide d'une formulation polymérisable. La formulation polymérisable peut comprendre un premier constituant comprenant un polymère de siloxane et un catalyseur, et un second constituant comprenant un polymère de siloxane et un agent de réticulation. Les premier et second constituants, lorsqu'ils sont combinés, peuvent former un film ou un joint d'étanchéité pourvu d'une élasticité qui diminue la formation de fibroblastes et/ou presse les ampoules et/ou diminue une cascade biochimique qui favorise la formation de cicatrices et/ou comprime la peau et/ou maintient la peau dans une configuration souhaitée.
PCT/US2016/057550 2016-10-18 2016-10-18 Kits, compositions et procédés de traitement et de recouvrement de la peau Ceased WO2018075018A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2016/057550 WO2018075018A1 (fr) 2016-10-18 2016-10-18 Kits, compositions et procédés de traitement et de recouvrement de la peau

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/057550 WO2018075018A1 (fr) 2016-10-18 2016-10-18 Kits, compositions et procédés de traitement et de recouvrement de la peau

Publications (1)

Publication Number Publication Date
WO2018075018A1 true WO2018075018A1 (fr) 2018-04-26

Family

ID=62019592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/057550 Ceased WO2018075018A1 (fr) 2016-10-18 2016-10-18 Kits, compositions et procédés de traitement et de recouvrement de la peau

Country Status (1)

Country Link
WO (1) WO2018075018A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097021A3 (fr) * 2018-11-05 2020-08-13 Inspired Material Solutions, LLC Agent de protection dermique et excipient
WO2020076367A3 (fr) * 2018-05-22 2020-10-01 Mencanin Steve Traitement de la peau
US12115220B2 (en) 2018-11-05 2024-10-15 Inspired Material Solutions, LLC Oral mucosal carrier and protectant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125948B2 (en) * 2002-10-04 2006-10-24 Shin-Etsu Chemical Co., Ltd. Silicone adhesive and silicone adhesive film
US7750106B2 (en) * 2005-12-21 2010-07-06 Avon Products, Inc. Cosmetic compositions having in-situ hydrosilylation cross-linking
US20100282410A1 (en) * 2007-08-02 2010-11-11 Bluestar Silicones France Sas Adhesive silicone elastomer composition
US7842771B2 (en) * 2006-05-11 2010-11-30 Wacker Chemie Ag Self-adhesive addition-crosslinking silicone compositions
WO2012030984A2 (fr) * 2010-08-31 2012-03-08 Living Proof, Inc. Compositions pour la peau et leurs applications
US9511034B1 (en) * 2013-12-09 2016-12-06 Bio-Silicote, Inc. Method for applying a skin treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125948B2 (en) * 2002-10-04 2006-10-24 Shin-Etsu Chemical Co., Ltd. Silicone adhesive and silicone adhesive film
US7750106B2 (en) * 2005-12-21 2010-07-06 Avon Products, Inc. Cosmetic compositions having in-situ hydrosilylation cross-linking
US7842771B2 (en) * 2006-05-11 2010-11-30 Wacker Chemie Ag Self-adhesive addition-crosslinking silicone compositions
US20100282410A1 (en) * 2007-08-02 2010-11-11 Bluestar Silicones France Sas Adhesive silicone elastomer composition
WO2012030984A2 (fr) * 2010-08-31 2012-03-08 Living Proof, Inc. Compositions pour la peau et leurs applications
US9511034B1 (en) * 2013-12-09 2016-12-06 Bio-Silicote, Inc. Method for applying a skin treatment

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076367A3 (fr) * 2018-05-22 2020-10-01 Mencanin Steve Traitement de la peau
WO2020097021A3 (fr) * 2018-11-05 2020-08-13 Inspired Material Solutions, LLC Agent de protection dermique et excipient
US11071786B2 (en) 2018-11-05 2021-07-27 Inspired Material Solutions, LLC Dermal skin protectant and carrier
CN113347982A (zh) * 2018-11-05 2021-09-03 因斯拜尔材料配方有限责任公司 真皮皮肤保护剂和载体
US11690916B2 (en) 2018-11-05 2023-07-04 Inspired Material Solutions, LLC Dermal skin protectant and carrier
US12115220B2 (en) 2018-11-05 2024-10-15 Inspired Material Solutions, LLC Oral mucosal carrier and protectant
US12419959B2 (en) 2018-11-05 2025-09-23 Inspired Material Strategies, LLC Dermal skin protectant and carrier

Similar Documents

Publication Publication Date Title
US11389561B2 (en) Methods for applying a skin treatment
US8859618B2 (en) Silicone gel-based compositions for wound healing and scar reduction
CN101010065B (zh) 含有止汗剂的聚硅氧烷粘合剂配方
AU2012319004B2 (en) Sacrificial adhesive coatings
US6572878B1 (en) Method and device for treating scars
RU2332238C2 (ru) Композиция для прокладок, раневых повязок и других изделий, контактирующих с кожей
JP2011200657A (ja) 長時間接してとどまっている包帯
EP1020198A2 (fr) Pansement résistant au froissement
CN107847357A (zh) 贴附材料、以及贴附材料中使用的贴附材料用支承体
ES2691407T3 (es) Vendajes adhesivos antimicrobianos
WO2018075018A1 (fr) Kits, compositions et procédés de traitement et de recouvrement de la peau
JP2007514011A (ja) シリコーンゲルをプラスチックに接着させるための方法
US20220305172A1 (en) Kits, compositions and methods for wound treatment and management
CN109836533A (zh) 一种液体创可贴及其制备工艺
WO2018052951A1 (fr) Kits, compositions et procédés pour le traitement et la gestion de plaies
US10660985B2 (en) Kits, compositions and methods for wound treatment and management
KR101998167B1 (ko) 통기성을 갖는 필름을 형성하는 창상피복용 조성물
WO2022226857A1 (fr) Pansement humide destiné à la protection de couleur de tatouage et son procédé d'utilisation
Worley So, what do I put on this wound? The wound dressing puzzle: Part III.
JP2007135673A (ja) 体表面用貼付材
TW201446220A (zh) 防疤貼片
Quinn 3 Clinical Approaches to the Use of Cyanoacrylate
HK1200185B (en) Sacrificial adhesive coatings

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16919219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16919219

Country of ref document: EP

Kind code of ref document: A1